RSV universal prophylaxis with monoclonal antibody reduces hospitalizations in Italy

The respiratory syncytial virus (RSV) has long driven seasonal spikes in pediatric visits, hospital admissions and intensive‑care demand, especially among infants under six months. Experts highlighted a new universal prophylaxis that uses a ready‑made monoclonal antibody, administered before exposure, to block the virus from entering respiratory cells. A single dose can protect infants throughout the peak months of the RSV season and can be given as early as the second day of life.

Safety data are reassuring: about 11 million children worldwide have been immunised with the antibody and no significant adverse effects have been reported. In Italy, the approach is expected to ease pressure on pediatric intensive‑care units, prevent delays of surgeries, and lower the number of severe bronchiolitis cases that previously required ventilation support. National guidelines stress that the antibody is not a vaccine and that routine use of steroids, bronchodilators or antibiotics is not recommended for bronchiolitis.

The prophylaxis represents a major shift in clinical practice for newborns and young infants, offering immediate protection against a virus that almost all children encounter in their first year.